This similarity suggests that β-PGG inhibits activation of the PI3K/Akt signaling pathway in a manner that resembles PCID2 silencing, implying that the anti-HCC effects of β-PGG may be mediated, at least in part, through targeting the PCID2-PI3K/Akt axis. The gene discussed is PCID2; the disease is hepatocellular carcinoma.